ReportWire

Tag: Wedbush

  • Wedbush Securities joins downtown L.A. exodus, opting for smaller, more flexible office in Pasadena

    Wedbush Securities joins downtown L.A. exodus, opting for smaller, more flexible office in Pasadena

    [ad_1]

    One of downtown Los Angeles’ familar tenants is pulling up stakes as the office rental market continues to contract from shrinking occupancy stoked by the pandemic.

    Financial services firm Wedbush Securities has begun its move from a prominent office tower to Pasadena, where it will occupy much smaller offices meant to accommodate employees who now work remotely much of the time.

    The firm is leaving behind Wedbush Center, which overlooks the Harbor Freeway and sports two signs on top bearing the company name. Wedbush has been headquartered in the Wilshire Boulevard building since 2001 and its lease expires next year.

    “It’s a big deal, a very big decision for the firm,” President Gary Wedbush said of the move. “The pandemic and COVID created a different kind of office for us.”

    With most employees required to be in the office only a third of the time, Wedbush is creating an office oriented toward shared workspaces that can be used as needed by various employees instead of assigned desks, he said.

    The move was also influenced by the changed nature of downtown’s financial district since thousands of office workers departed during the COVID-related shutdown and probably won’t return again in pre-pandemic numbers. Many shops and restaurants remain closed and office tenants have said the streets feel less safe than they used to.

    Although Wedbush said “downtown has been fantastic for us,” other locations have become more attractive. “There are places like Pasadena that seem to have recovered more fully from the pandemic than downtown Los Angeles has. That was a part of the decision-making” to move.

    The firm leases more than 100,000 square feet at Wedbush Center but will occupy about 20,000 square feet in an office complex on Lake Avenue in one of Pasadena’s leading commercial districts.

    “The amenities on Lake Avenue are fantastic,” Wedbush said. “Casual restaurants to really fine dining, fitness centers — it just had everything.”

    Wedbush’s move, which will take place formally in the first half of 2025, reflects a trend that has been affecting downtown and much of Los Angeles County for the last few years, real estate brokerage CBRE said in a recent report on office leasing.

    “The Greater Los Angeles office market continued its search for the bottom” in the third quarter, CBRE said, as both tenants and landlords “navigate the ongoing supply and demand imbalance exacerbated by the shift to hybrid and remote work.”

    Companies adapting to new work models are leaving behind large chunks of office space, and the change is particularly noticeable downtown, where CBRE said overall vacancy is more than 30%, triple the amount considered to be a healthy balance between tenant and landlord interests.

    Wedbush Securities’ shift to hybrid work, with people in the office some days and not others, created the chance to make a different kind of office with a smaller footprint and more shared spaces to collaborate or work away from a traditional desk, Wedbush said.

    About 70% of the office will be considered “hotel” space where employees can choose a workstation on days they are present while the remaining 30% will be offices for financial advisors and others who need privacy to meet with clients.

    A stark difference will be that the shared workstations will be around the windows with views of the city and the offices will be in the center of the building. In the old arrangement, individual offices were much larger and occupied the prime space along the windows, Wedbush said.

    One of the two floors Wedbush Securities leased in Pasadena has a rooftop deck that Wedbush plans to make into an outdoor office space with conference tables, workstations where people can plug in their computers and places to unwind.

    “It’s not just going to be a couple of tables and umbrellas,” he said. “The opportunity to build out this new space was a big driver in us moving out of our building that we’ve loved for so, so many years.”

    Wedbush Securities was co-founded in 1955 by Wedbush’s father, Edward, in Los Angeles and now has close to 900 employees in 28 cities across the country, Wedbush said. “We’re really proud of our Los Angeles legacy.”

    Wedbush’s decision to dramatically shrink its headquarters underscores not only the continued struggles of the office rental market in the wake of the pandemic but broader vulnerabilities in commercial real estate throughout L.A. County.

    A report released by real estate services firm NAI Capital said that in the third quarter of 2024, Los Angeles County’s commercial real estate market experienced a sharp 18.4% year-to-date decline in sales volume and a rise in real estate cap rates, a metric used to estimate an investor’s rate of return based on the income that the property is expected to generate.

    It may be a low point in the real estate cycle for property sales, NAI Capital Chief Executive Chris Jackson said.

    “With cap rates on the rise, California regulations, and high interest rates throughout 2024, the commercial real estate market took a bit of a dip” with office properties “hit particularly hard,” Jackson said. “However, with interest rates expected to decline more substantially in 2025, we anticipate a significant rebound in real estate sales.”

    Sales are being further limited by taxes and government fees, particularly Measure ULA, the property transfer tax in Los Angeles that took effect in 2023, the report said. Dubbed the “mansion tax,” Measure ULA imposed a 4% tax on real estate transactions over $5 million and a 5.5% tax on those exceeding $10 million. In June, those thresholds increased to $5.15 million and $10.3 million.

    The tax has contributed to a nearly 40% year-over-year drop in sales of office, retail, industrial and multifamily properties, or $1.9 billion below last year’s total, the report said.

    [ad_2]

    Roger Vincent

    Source link

  • Theseus Pharmaceuticals (NASDAQ:THRX) PT Lowered to $7.00

    Theseus Pharmaceuticals (NASDAQ:THRX) PT Lowered to $7.00

    [ad_1]

    Theseus Pharmaceuticals (NASDAQ:THRXGet Free Report) had its target price cut by analysts at Wedbush from $24.00 to $7.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 163.16% from the company’s current price.

    A number of other analysts have also recently weighed in on the stock. HC Wainwright decreased their price target on shares of Theseus Pharmaceuticals from $22.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC downgraded Theseus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Theseus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

    Theseus Pharmaceuticals Price Performance

    Theseus Pharmaceuticals stock opened at $2.66 on Friday. The company has a market cap of $115.91 million, a price-to-earnings ratio of -1.94 and a beta of 4.03. Theseus Pharmaceuticals has a 12 month low of $2.62 and a 12 month high of $14.77. The stock’s 50-day moving average is $9.46 and its 200-day moving average is $9.64.

    Theseus Pharmaceuticals (NASDAQ:THRXGet Free Report) last posted its quarterly earnings results on Thursday, May 11th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. Research analysts anticipate that Theseus Pharmaceuticals will post -1.58 EPS for the current year.

    Hedge Funds Weigh In On Theseus Pharmaceuticals

    A number of institutional investors and hedge funds have recently added to or reduced their stakes in THRX. Tower Research Capital LLC TRC increased its stake in shares of Theseus Pharmaceuticals by 66.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,420 shares of the company’s stock worth $26,000 after buying an additional 1,757 shares during the last quarter. Barclays PLC increased its position in shares of Theseus Pharmaceuticals by 76.0% in the 4th quarter. Barclays PLC now owns 8,904 shares of the company’s stock worth $44,000 after purchasing an additional 3,844 shares during the last quarter. American International Group Inc. raised its stake in shares of Theseus Pharmaceuticals by 39.2% in the 2nd quarter. American International Group Inc. now owns 7,952 shares of the company’s stock valued at $44,000 after purchasing an additional 2,238 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Theseus Pharmaceuticals by 68.3% during the second quarter. JPMorgan Chase & Co. now owns 9,084 shares of the company’s stock worth $50,000 after purchasing an additional 3,687 shares during the last quarter. Finally, Morgan Stanley grew its stake in Theseus Pharmaceuticals by 31.1% in the fourth quarter. Morgan Stanley now owns 11,478 shares of the company’s stock worth $57,000 after purchasing an additional 2,721 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

    Theseus Pharmaceuticals Company Profile

    (Get Free Report)

    Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

    Featured Stories

    Analyst Recommendations for Theseus Pharmaceuticals (NASDAQ:THRX)

    Receive News & Ratings for Theseus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Wedbush Trims Home Depot (NYSE:HD) Target Price to $290.00

    Wedbush Trims Home Depot (NYSE:HD) Target Price to $290.00

    [ad_1]

    Home Depot (NYSE:HDGet Rating) had its target price cut by Wedbush from $300.00 to $290.00 in a research report report published on Wednesday morning, The Fly reports. Wedbush also issued estimates for Home Depot’s Q2 2024 earnings at $4.37 EPS, Q3 2024 earnings at $3.74 EPS, Q4 2024 earnings at $2.82 EPS, FY2024 earnings at $14.76 EPS, FY2025 earnings at $15.84 EPS and FY2026 earnings at $16.91 EPS.

    A number of other brokerages have also commented on HD. Citigroup cut their price target on Home Depot from $332.00 to $327.00 in a report on Wednesday, May 10th. Sanford C. Bernstein cut their price target on Home Depot from $333.00 to $314.00 in a report on Wednesday. Piper Sandler cut their price target on Home Depot from $320.00 to $300.00 in a report on Wednesday, February 15th. Bank of America lowered their price objective on Home Depot from $360.00 to $346.00 in a research report on Wednesday, February 22nd. Finally, UBS Group lowered their price objective on Home Depot from $350.00 to $340.00 and set a buy rating on the stock in a research report on Wednesday, February 22nd. Thirteen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $323.25.

    Home Depot Stock Down 1.5 %

    HD opened at $290.88 on Wednesday. Home Depot has a twelve month low of $264.51 and a twelve month high of $347.25. The firm has a market cap of $294.57 billion, a P/E ratio of 17.73, a price-to-earnings-growth ratio of 1.89 and a beta of 0.93. The business has a 50 day moving average price of $290.67 and a 200 day moving average price of $306.12. The company has a debt-to-equity ratio of 113.02, a quick ratio of 0.33 and a current ratio of 1.27.

    Home Depot (NYSE:HDGet Rating) last issued its quarterly earnings results on Tuesday, May 16th. The home improvement retailer reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.02. Home Depot had a return on equity of 1,936.63% and a net margin of 10.75%. The company had revenue of $37.26 billion during the quarter, compared to analyst estimates of $38.35 billion. During the same period in the previous year, the company earned $4.09 earnings per share. The company’s quarterly revenue was down 4.2% compared to the same quarter last year. Research analysts forecast that Home Depot will post 15.01 EPS for the current year.

    Home Depot Announces Dividend

    The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, June 1st will be issued a dividend of $2.09 per share. This represents a $8.36 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Wednesday, May 31st. Home Depot’s payout ratio is presently 50.94%.

    Insider Activity

    In other news, EVP Hector A. Padilla sold 1,502 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $293.09, for a total transaction of $440,221.18. Following the transaction, the executive vice president now owns 13,958 shares of the company’s stock, valued at $4,090,950.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.19% of the stock is currently owned by insiders.

    Hedge Funds Weigh In On Home Depot

    Several large investors have recently made changes to their positions in HD. Slow Capital Inc. acquired a new position in Home Depot in the first quarter valued at about $25,000. Kalos Management Inc. acquired a new position in Home Depot in the first quarter valued at about $26,000. Fairfield Bush & CO. acquired a new position in Home Depot in the first quarter valued at about $27,000. Glassy Mountain Advisors Inc. acquired a new position in Home Depot in the fourth quarter valued at about $30,000. Finally, KB Financial Partners LLC acquired a new position in Home Depot in the first quarter valued at about $28,000. Institutional investors and hedge funds own 68.31% of the company’s stock.

    Home Depot Company Profile

    (Get Rating)

    The Home Depot, Inc engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and equipment rental.

    Further Reading

    The Fly logo

    Analyst Recommendations for Home Depot (NYSE:HD)

    Receive News & Ratings for Home Depot Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Home Depot and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link